1. Wang MK, Binbraik Y, Riekki T, Devereaux PJ. Morbidity and mortality in pulmonary hypertension after non-cardiac surgery: a systematic review and meta-analysis. J Am Coll Cardiol 2021; 77 (18 Suppl 1): 1678-1678. DOI: 10.1016/S0735-1097(21)03034-5.
2.
McGlothlin D, Ivascu N, Heerdt PM. Anesthesia and pulmonary hypertension. Prog Cardiovasc Dis 2012; 55: 199-217. DOI: 10.1016/j.pcad.2012. 08.002.
3.
Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J 2019; 53: 1802148. DOI: 10.1183/13993003.02148-2018.
4.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl): D34-D41. DOI: 10.1016/j.jacc.2013.10.029.
5.
Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, et al. Management of pulmonary arterial hypertension. Curr Cardiovasc Risk Rep 2021; 15: 2. DOI: 10.1007/s12170-020-00663-3.
6.
Denault AY, Bussieres JS, Arellano R, Finegan B, Gavra P, Haddad F, et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Can J Anaesth 2016; 63: 1140-1153. DOI: 10.1007/s12630-016-0709-8.
7.
Rex S, Busch T, Vettelschoss M, de Rossi L, Rossaint R, Buhre W. Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost. Anesthesiology 2003; 99: 745-747. DOI: 10.1097/00000542-200309000- 00033.
8.
Winterhalter M, Steffen R, Stoppe C, Kienbaum P, Müller HH, Kaufmann I, et al. Effect of iloprost inhalation on postoperative outcome in high-risk cardiac surgical patients: a prospective randomized-controlled multicentre trial (ILOCARD). Can J Anaesth 2019; 66: 907-920. DOI: 10.1007/s12630-019-01309-8.
9.
Rao V, Ghadimi K, Keeyapaj W, Parsons CA, Cheung AT. Inhaled nitric oxide (iNO) and inhaled epoprostenol (iPGI2) use in cardiothoracic surgical patients: is there sufficient evidence for evidence-based recommendations? J Cardiothorac Vasc Anesth 2018; 32: 1452-1457. DOI: 10.1053/ j.jvca.2017.12.014.
10.
Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2018; 22: 406-413. DOI: 10.1053/j.jvca. 2007.10.015.
11.
Hoeper MM, Olschewski H, Ghofrani HA, Wil- kens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35: 176-182. DOI: 10.1016/s0735-1097(99)00494-5.
12.
Strumpher J, Jacobsohn E. Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. J Cardiothorac Vasc Anesth 2011; 25: 687-704. DOI: 10.1053/j.jvca. 2011.02.022.
13.
Theodoraki K, Thanopoulos A, Rellia P, Leontiadis E, Zarkalis D, Perreas K, Antoniou T. A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension. Heart Vessels 2017; 32: 1488-1497. DOI: 10.1007/s00380-017-1023-2.
14.
Patel J, Patel K, Garg P, Patel S. Inhaled versus intravenous milrinone in mitral stenosis with pulmonary hypertension. Asian Cardiovasc Thorac Ann 2021; 29: 170-178. DOI: 10.1177/0218492320970015.
15.
Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013; 41: 1302-1307. DOI: 10.1183/ 09031936.00089212.
16.
Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26: 462-468. DOI: 10.1007/s12325-009-0019-4.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
